Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM IN PLASTIC CONTAINER versus LIQUAEMIN SODIUM PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM IN PLASTIC CONTAINER versus LIQUAEMIN SODIUM PRESERVATIVE FREE.
HEPARIN SODIUM IN PLASTIC CONTAINER vs LIQUAEMIN SODIUM PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, inducing conformational change that accelerates its inhibition of thrombin (factor IIa), factor Xa, and other coagulation factors (IXa, XIa, XIIa).
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin) and Xa, thereby preventing thrombus formation and extension.
Initial IV bolus of 80 units/kg followed by continuous IV infusion of 18 units/kg/hour; dose adjusted based on aPTT. Typical infusion range 10-30 units/kg/hour. Subcutaneous route: 5000 units every 8-12 hours for prophylaxis.
Intravenous: Initial bolus of 80 units/kg followed by continuous infusion at 18 units/kg/hour; subcutaneous: 5000 units every 8-12 hours.
None Documented
None Documented
30-150 minutes (dose-dependent: 0.5-1.5 h at low doses, up to 2.5 h at high doses). Prolonged in hepatic or renal impairment.
Terminal elimination half-life: 1-2 hours (0.5-1.5 h at therapeutic doses, dose-dependent due to saturable clearance). Context: shorter half-life in pulmonary embolism, prolonged in hepatic/renal impairment. Protamine reversal used for rapid offset.
Renal (predominantly), with minor biliary/fecal elimination. Clearance is dose- and concentration-dependent due to saturable binding.
Renal: 50-70% as unchanged heparin and metabolites via saturable clearance; biliary/fecal: <5% as metabolites.
Category A/B
Category C
Anticoagulant
Anticoagulant